
    
      This is a multi-center study perform at three tertiary university hospitals. Patients with H.
      pylori infection will be treated according to their DPO-PCR results. Patients who are
      susceptible to clarithromycin will be randomized to receive either triple therapy for 7-days
      or 14-days. Patients who are resistant to clarithromycin will be randomized to receive either
      bismuth quadruple therpay for 7-days or 14-days. The eradication rates of each regimens and
      the adverse events of each regimen will be investigated.
    
  